Atalanta Gets $97 Million Series B to Target Neurological Disorders With RNAi
Atalanta Therapeutics, a Boston-based biotechnology company focused on neurological diseases, announced Monday the completion of a $97 million series B financing round. The raise was co-led by the Dutch venture firm EQT Life Sciences and Sanofi’s venture …